Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
3 hedge funds and large institutions have $40.2M invested in Plus Therapeutics in 2014 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
13% more capital invested
Capital invested by funds: $35.4M → $40.2M (+$4.77M)
0% more funds holding
Funds holding: 3 → 3 (0)
84% less call options, than puts
Call options by funds: $70K | Put options by funds: $434K
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$140K |
| 2 |
Jane Street
New York
|
-$121K |
| 3 |
Renaissance Technologies
New York
|
-$119K |
| 4 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$109K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$104K |
PSTV Hedge Fund Activity: Q1 2014 in Review
3 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q1 2014, worth a combined $40.2M — up 13% from $35.4M a quarter earlier.
Fund positioning in PSTV was balanced in Q1 2014: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Millennium Management, cutting an estimated $140K.
- 3 institutional investors held Plus Therapeutics (PSTV) as of Q1 2014, unchanged from Q4 2013.
- Funds reported $40.2M of Plus Therapeutics stock for Q1 2014, up 13% quarter-over-quarter.
- 0 funds opened new Plus Therapeutics positions in Q1 2014 and 0 closed out.
- The largest Plus Therapeutics seller in Q1 2014 was Millennium Management, an estimated $140K sold.
Based on aggregated 13F filings for Q1 2014.